Pilot Study of the Antibody-drug Conjugate Glembatumumab Vedotin (CDX-011) Following Doxorubicin (Adriamycin) and Cytoxan as Neo-adjuvant Therapy in Glycoprotein NMB-expressing High Risk Triple Negative Breast Cancer

Trial Profile

Pilot Study of the Antibody-drug Conjugate Glembatumumab Vedotin (CDX-011) Following Doxorubicin (Adriamycin) and Cytoxan as Neo-adjuvant Therapy in Glycoprotein NMB-expressing High Risk Triple Negative Breast Cancer

Withdrawn prior to enrolment
Phase of Trial: Phase 0

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Cyclophosphamide (Primary) ; Doxorubicin (Primary) ; Glembatumumab vedotin (Primary)
  • Indications Breast cancer
  • Focus Adverse reactions
  • Acronyms Breast50
  • Most Recent Events

    • 30 May 2018 Planned End Date changed from 31 Mar 2023 to 31 May 2018.
    • 30 May 2018 Planned primary completion date changed from 31 Mar 2021 to 2 May 2018.
    • 30 May 2018 Planned initiation date changed from 31 Mar 2018 to 1 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top